State of Wisconsin Investment Board increased its position in shares of Impax Laboratories, Inc. (NASDAQ:IPXL) by 125.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 280,616 shares of the specialty pharmaceutical company’s stock after buying an additional 155,963 shares during the period. State of Wisconsin Investment Board owned 0.39% of Impax Laboratories worth $4,518,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IPXL. Vanguard Group Inc. raised its position in Impax Laboratories by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company’s stock worth $79,080,000 after buying an additional 276,765 shares during the period. North Tide Capital LLC raised its position in Impax Laboratories by 50.0% in the first quarter. North Tide Capital LLC now owns 3,000,000 shares of the specialty pharmaceutical company’s stock worth $37,950,000 after buying an additional 1,000,000 shares during the period. Dimensional Fund Advisors LP raised its position in Impax Laboratories by 47.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,637,077 shares of the specialty pharmaceutical company’s stock worth $33,359,000 after buying an additional 845,375 shares during the period. Frontier Capital Management Co. LLC bought a new position in Impax Laboratories during the first quarter worth $14,012,000. Finally, Point72 Asset Management L.P. raised its position in Impax Laboratories by 88.4% in the first quarter. Point72 Asset Management L.P. now owns 1,095,600 shares of the specialty pharmaceutical company’s stock worth $13,859,000 after buying an additional 514,200 shares during the period. 86.26% of the stock is owned by institutional investors.

Impax Laboratories, Inc. (NASDAQ:IPXL) opened at 21.45 on Friday. The stock’s market capitalization is $1.54 billion. Impax Laboratories, Inc. has a 1-year low of $7.75 and a 1-year high of $27.29. The stock has a 50 day moving average price of $18.24 and a 200-day moving average price of $14.94.

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The business’s quarterly revenue was up 17.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 earnings per share. Equities research analysts expect that Impax Laboratories, Inc. will post $0.70 EPS for the current year.

WARNING: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/02/state-of-wisconsin-investment-board-has-4-52-million-position-in-impax-laboratories-inc-ipxl.html.

A number of research analysts recently weighed in on IPXL shares. BidaskClub lowered Impax Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Zacks Investment Research lowered Impax Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Royal Bank Of Canada set a $17.00 price objective on Impax Laboratories and gave the company a “hold” rating in a research report on Thursday, August 10th. BMO Capital Markets reaffirmed a “hold” rating and set a $16.00 price objective on shares of Impax Laboratories in a research report on Friday, June 23rd. Finally, Janney Montgomery Scott reaffirmed a “neutral” rating and set a $21.00 price objective on shares of Impax Laboratories in a research report on Monday, June 12th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company’s stock. Impax Laboratories currently has an average rating of “Hold” and an average price target of $17.85.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.